Abstracts Archive - Page 156 of 2607 - ACR Meeting Abstracts

Abstract Number: 0795 • ACR Convergence 2025
Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response
Ismael Sanchez-Pareja¹, Daniel Toro², Carlos Pérez Sánchez³, Laura muñoz-Barrera¹, Tomás Cerdó¹, Elena Moreno-Caño⁴, Sagrario Corrales¹, Lydia Formanti Alonso⁵, Rafaela Ortega-Castro⁶, Jerusalén Calvo⁵, Lourdes Ladehesa⁷, Concepción Aranda-Valera⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero Contreras⁵ and Chary López pedrera¹⁰, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²GENYO / Karolinska Institutet, Granada / Stockholm, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: To characterize molecular profiles of RA patients through multi-omics integration and evaluate their associations with disease status and therapeutic response to csDMARDs, TNF inhibitors…
Abstract Number: 0534 • ACR Convergence 2025
Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort
Clementina López Medina¹, Sylvie Chevret², Cedric Lukas³, Anna Molto⁴ and Maxime Dougados², ¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ²Université Paris-Cité, Paris, France, ³CHU Montpellier, Montpellier, France, ⁴Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Concomitant fibromyalgia (FM) can be suspected in patients (pts) with axial SpA (axSpA) using the Fibromyalgia Rapid Screening Tool (FiRST).The objective of this study…
Abstract Number: 0761 • ACR Convergence 2025
Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis
Tiago Beirão¹, Catarina Rua¹, Catarina Silva¹, Mariana Patela¹, Romana Vieira¹, Joana Abelha-aleixo¹, Patrícia Pinto¹, Flávio Costa¹, Ana Sofia Pinto¹, Diogo Fonseca¹, Tiago Meirinhos¹, Ajexandro Souto² and Taciana Videira¹, ¹Unidade Local de Saude Gaia e Espinho, Porto, Portugal, ²Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Giant Cell Arteritis (GCA) is a chronic, inflammatory condition, primary affecting the medium and larger arteries, usually in patients older than 50 years. It…
Abstract Number: 0770 • ACR Convergence 2025
Interrelationships of Depression, Pain, and Gait Mechanics and their Associations with Physical Activity Levels Among People with Knee Osteoarthritis
Oiza Peters, Steven Garcia, Joy Itodo, Ogundoyin Ogundiran and kharma Foucher, UNIVERSITY OF ILLINOIS, CHICAGO, Chicago, IL
Background/Purpose: Depression is associated with low physical activity (PA) levels in people with knee osteoarthritis (KOA)1. Pain contributes to both depression and PA levels in…
Abstract Number: 0740 • ACR Convergence 2025
Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Carmen Secada-Gómez¹, Javier Loricera², Adrian Martin-Gutierrez³, Santos Castañeda⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Aortitis associated to Giant cell arteritis (GCA) (GCA-aortitis) is one of the most severe manifestation of GCA. Tocilizumab (TCZ) has demonstrated efficacy in large-vessel…
Abstract Number: 0788 • ACR Convergence 2025
Spatiotemporal Gait Differences Between Fallers and Non-Fallers in People with Knee Osteoarthritis
Joy Itodo, Steven Garcia, Oiza Peters, Ogundoyin Ogundiran and Kharma Foucher, UNIVERSITY OF ILLINOIS, CHICAGO, Chicago, IL

Background/Purpose: People with knee osteoarthritis (OA) have higher fall rates than their age-matched peers. Studies in another at-risk group, healthy older adults, have linked fall…
Abstract Number: 0784 • ACR Convergence 2025
Physical Activity and Exercise Therapy Reduce the Transition from Acute to Chronic Low Back Pain in the Community
Katlin Harker¹, Rebecca Fillipo² and Adam Goode², ¹Durham VA, Durham, ²Duke University, Durham
Background/Purpose: Physical activity (PA) and exercise therapy are guideline-supported interventions for chronic LBP, but their influence on the transition from acute to chronic LBP is…
Abstract Number: 0808 • ACR Convergence 2025
Spatial Transcriptomics Show Fibroblast LIF Receptor Drives Fibrosis in Systemic Sclerosis
Mari Kamiya¹, Hung Nguyen¹, Miles Tran², Ce Gao³, Sergio Poli¹, Yunju Jeong⁴, Louis Merriam⁵, Jinjun Shi⁶, Rachel Knipe⁷, Katharine Black⁸, Lida Hariri⁹, Carol Feghali-Bostwick¹⁰, Rodney Infante¹¹, Janelle Pugashetti¹², Justin Oldham¹², Ilya Korsunsky¹³, Kevin Wei¹⁴ and Edy Kim¹, ¹Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH); Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, MA, United States; Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul, Republic of Korea, ⁵Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH), Boston, MA, ⁶Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital (BWH); Harvard Medical School, Boston, MA, ⁷Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁸Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁹Department of Pathology, Massachusetts General Hospital; Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Center for Human Nutrition, Dept. of Molecular Genetics, DOM, University of Texas Southwestern, Dallas, TX, ¹²Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, ¹³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Division of Genetics, DOM, BWH; Harvard Medical School, Boston, MA, ¹⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibroinflammatory disease of skin and visceral organs. Current SSc therapies have limited efficacy for progressive fibrosis. Our prior…
Abstract Number: 0545 • ACR Convergence 2025
Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
Omar-Javier Calixto¹, Uta Kiltz², Brikena Lalazi³, Franziska Neinert³, Philipp Sewerin⁴ and Xenofon Baraliakos², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque, Herne, Nordrhein-Westfalen, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany
Background/Purpose: The phenotypes of axial spondyloarthritis (axSpA) and clinical responses to placebo and study drugs in randomized controlled trials (RCTs) have changed over time. We…
Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 0798 • ACR Convergence 2025
Inhibition of Wnt Signaling Attenuates Inflammatory Arthritis Severity
Alisa Mueller¹, Angela Zou², Lucy-Jayne Marsh³, Samuel Kemble³, Saba Nayar³, Gerald Watts⁴, Cassandra Murphy⁵, Emily Taylor³, Triin Major³, David Gardner⁶, Christopher Buckley⁷, Kevin Wei⁸, Soumya Raychaudhuri⁵, ilya Korsunsky⁵, Andrew Filer⁹, Adam Croft¹⁰ and Michael Brenner¹¹, ¹Stanford University and VA Palo Alto Health Care System, Stanford, CA, ²Harvard Medical School, Boston, MA, ³University of Birmingham, Birmingham, United Kingdom, ⁴Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶University of Birmingham, Havelock North, New Zealand, ⁷University of Oxford, Oxford, United Kingdom, ⁸Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁹The University of Birmingham, Birmingham, United Kingdom, ¹⁰University of Birmingham, Hagley, Stourbridge, United Kingdom, ¹¹Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Fibroblasts are critical in promoting pathogenic synovial inflammation and bone erosion in rheumatoid arthritis (RA). Moreover, recent studies have pointed to their potential contribution…
Abstract Number: 0773 • ACR Convergence 2025
Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima², Motohiro Nonaka³, Norimichi Nomura⁴, Atsubumi Ogawa¹, Yasuhiro Nohda¹, Mirei Shirakashi², Ryosuke Hiwa¹, Hideaki Tsuji¹, Hajime Yoshifuji², Shogo Matsuda⁵, Masao Katsushima⁶, Michinori Ishitoku⁷, Yusuke Yoshida⁷, Yasuyuki Todoroki⁸, Satoshi Kubo⁹, Tomohiro Handa¹⁰, Hiromi Tomioka¹¹, Ryo Tachikawa¹², Keisuke Tomii¹², Kiminobu Tanizawa¹³, Toru Arai¹⁴, Takuya Kotani¹⁵, Motomu Hashimoto¹⁶, Shintaro Hirata⁷, Yoshiya Tanaka¹⁷, Tsuneyo Mimori¹⁸ and Akio Morinobu¹⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ³Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶Department of Clinical Immunology, Osaka Metropolitan Graduate School of Medicine, Osaka, Japan, ⁷Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁸Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Department of Advanced Medicine for Respiratory Failure and Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹¹Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan, ¹²Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan, ¹³Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, ¹⁴Clinical Research Center, NHO Kinki-Chuo Chest Medical Center, Sakai, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, ¹⁶Osaka Metropolitan University, Osaka, Japan, ¹⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁸Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ¹⁹Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Melanoma differentiation-associated gene 5 (MDA5) is a cytoplasmic RNA sensor and activates the innate immune response. Autoantibodies against MDA5 are associated with rapidly progressive…
Abstract Number: 0815 • ACR Convergence 2025
Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation
Eoin Kelleher¹, Amanda Wall¹, Isabelle Brennan², Robert Murphy¹, Antonella Delmis¹, John Davis³, Vishvarani Wanigasekera⁴, Irene Tracey¹ and Anushka Irani⁵, ¹University of Oxford, Oxford, United Kingdom, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴University of Oxford, Oxford, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Despite effective control of inflammation in rheumatoid arthritis (RA), persistent and severe pain remains a clinical challenge. Dysregulated pain processing in the central nervous…
Abstract Number: 0816 • ACR Convergence 2025
Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs
Andreas Kerschbaumer¹, Marlene Steiner², William H. Robinson³, Josef Smolen⁴ and Daniel Aletaha⁵, ¹Stanford University / Medical University of Vienna, Stanford, CA, ²Medical University of Vienna, Vienna, Wien, Austria, ³Stanford University, Palo Alto, CA, ⁴Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Joint swelling and tenderness are clinical hallmarks of rheumatoid arthritis (RA) and central to disease assessment. Regardless of treatment type, stringent remission based on…
Abstract Number: 0812 • ACR Convergence 2025
Anti-CD206 CAR T Cell Immunotherapy Mitigates Dermal Pathology in Systemic Sclerosis
Chanhyuk Park¹, Helen Jarnagin², Asmaa Mohamed³, Noelle Kosarek⁴, Owen Wilkins¹, Fred Kolling¹, Yina Huang¹, Michael Whitfield⁵ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Charlottesville, VA, ⁴Dartmouth Geisel School of Medicine, Lebanon, NH, ⁵Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a progressive, chronic multi-system disorder of unknown etiology that is characterized by immune dysfunction, fibrosis, and loss of dermal white…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].